IGF1R Mutant Cell Lines Eliminate IGF-1 Supplement Costs

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The high cost of biologics manufacturing is largely due to the complexity of the production process, with insulin-like growth factor 1 (IGF-1) being a costly supplement in cell culture media, necessitating a reduction in costs associated with recombinant protein production.

Innovation Solution

Genetically modified mammalian cell lines with constitutively active Insulin-like Growth Factor 1 Receptor (IGF1R) mutants that can grow and produce proteins without the need for IGF-1 supplementation, using nucleic acids encoding these mutants stably integrated into the cell genome.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If IGF-1 is supplemented in cell culture media to support cell growth and protein production, then cell growth and productivity are maintained, but manufacturing costs increase significantly

Engineering Contradiction:

Improvecell growth and protein productionVSAvoidIGF-1 supplementation cost

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The cell line is engineered to produce its own IGF-1 through endogenous expression, eliminating the need for external IGF-1 supplementation in the culture media. The cell serves itself by synthesizing the growth factor it requires, thereby reducing manufacturing costs while maintaining growth and productivity

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The engineered cell line achieves multiple functions: it produces the recombinant protein of interest while simultaneously synthesizing IGF-1 to support its own growth and proliferation. This multi-functionality eliminates the need for separate IGF-1 supplementation

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Quantity of substance

If IGF-1 supplementation is reduced or eliminated to lower costs, then manufacturing costs decrease, but cell growth and productivity may be compromised

Engineering Contradiction:

ImproveIGF-1 supplementation costVSAvoidcell growth and protein production

Core Design Contradiction:

Quantity of substanceVSProductivity

Solution Approach 1:

The cell line is pre-engineered with integrated IGF-1 expression capability before culture initiation. This preliminary genetic modification ensures that IGF-1 is continuously produced from the outset, preventing any potential growth deficiency that might occur with IGF-1 reduction or elimination

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The cell autonomously produces IGF-1 through its engineered endogenous expression system, ensuring adequate levels are maintained for optimal growth and productivity without relying on external supplementation

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach reduces the requirement for IGF-1 in cell culture media, lowering production costs while maintaining growth rates and productivity comparable to IGF-1 supplemented cultures.

Implementation Method 1

Insulin-like growth factors are growth factors that through their binding to insulin-like growth factor receptors initiates intracellular signaling to regulate cell growth, proliferation and differentiation

Methodology Applied

Scientific EffectSignal transduction:

Data Source

PatentUS20230323287A1Overexpression of insulin-like growth factor receptor mutants to modulate IGF supplementation

Publication Date: 2023.10.12 AMGEN INC

AI summary

Methods of mammalian cell culture for expressing a recombinant protein of interest are provided. In various embodiments the methods relate to the mammalian cells expressing an IGF1R mutant that is constitutively active.